aTyr Pharma (LIFE)
(Delayed Data from NSDQ)
$1.60 USD
+0.03 (1.91%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.59 -0.01 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LIFE 1.60 +0.03(1.91%)
Will LIFE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LIFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LIFE
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
5 Top Stocks to Play Earnings Beat Potential
LIFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
5 Top Stocks Likely to Top Earnings Estimates
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
Other News for LIFE
12 Health Care Stocks Moving In Tuesday's After-Market Session
aTyr Pharma to Participate in April Investor Conferences
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
WW, ATNM and XTIA are among pre market gainers
3 Best Stocks to Buy Now, 3/18/2024, According to Top Analysts